Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of anthracycline-related cardiomyopathy in breast cancer
IRCT20151123025202N45Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Anthracycline Cardiomyopathy comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Heart failure prevention assessed by echocardiography, Left ventricular ejection fraction and 3 more. Started Apr 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
Anthracycline Cardiomyopathy
Beyond the preview
Go deeper on IRCT20151123025202N45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151123025202N45.